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ABSTRACT
ThetwoBRCTdomains(BRCT1andBRCT2)ofXRCC1
mediate a network of protein–protein interactions
with several key factors of the DNA single-strand
breaks (SSBs) and base damage repair pathways.
BRCT1 is required for the immediate poly(ADP–
ribose)-dependent recruitment of XRCC1 to DNA
breaksandisessentialforsurvivalafterDNAdamage.
To better understand the biological role of XRCC1 in
the processing of DNA ends, a search for the BRCT1
domain-associated proteins was performed by mass
spectrometry of GST-BRCT1 pulled-down proteins
from HeLa cell extracts. Here, we report that the
double-strand break (DSB) repair heterotrimeric
complex DNA-PK interacts with the BRCT1 domain
of XRCC1 and phosphorylates this domain at serine
371 after ionizing irradiation. This caused XRCC1
dimer dissociation. The XRCC1 R399Q variant allele
didnotaffectthisphosphorylation.Wealsoshowthat
XRCC1 strongly stimulates the phosphorylation of
p53-Ser15 by DNA-PK. The pseudo phosphorylated
S371D mutant was a much weaker stimulator of
DNA-PK activity whereas the non-phosphorylable
mutant S371L endowed with a DNA-PK stimulating
capacity failed to fully rescue the DSB repair defect
of XRCC1-deficient EM9 rodent cells. The functional
associationbetweenXRCC1andDNA-PKinresponse
to IR provides the first evidence for their involvement
in a common DSB repair pathway.
INTRODUCTION
DNA damage must be repaired to avoid genomic instability
and loss of information content that can lead to cancer (1,2).
Responding to single- and double-strand breaks requires
coordinated events including detection and signaling of the
DNA breaks and the sequential recruitment of repair enzymes.
XRCC1 (X-ray cross complementing factor 1) is a molecular
scaffold protein that coordinates the assembly of repair com-
plexes at damaged sites (3–5). XRCC1 interacts with enzym-
atic components including the 7,8-dihydro 8-oxo-guanine
glycosylase (OGG1) (6), APE1-endonuclease (7), the poly-
nucleotide kinase (PNK) which processes DNA termini (8)
and DNA polymerase b (pol b) (9). XRCC1 localizes to
sites of replication foci and interacts directly with PCNA
that links XRCC1 to the progression of DNA replication
(10). Interestingly, it was shown that XRCC1 is phos-
phorylated by the CK2 kinase and that the phosphorylation
sites reside within the linker region between the two
BRCTs. CK2 phosphorylation of XRCC1 stimulates binding
to either PNK (11) or aprataxin (12–14), in two preformed
complexes (12).
XRCC1 encompasses two BRCT motifs with independent
and important roles (15,16). The BRCT1 domain is the most
evolutionarily conserved and is required for survival after
methylation damage but its precise function is not fully under-
stood at present. It interacts with PARP-1 and PARP-2 and
limits their poly(ADP–ribosyl)ating activities (17,18). The
BRCT1 contains a binding site for poly(ADP–ribose)
(PAR) (19). As a consequence, in response to the activation
of PARP-1 by single-strand breaks (SSBs), XRCC1 is
recruited within seconds to the sites of chromosomal DNA
strand breakage by its BRCT1 domain (3–5). The BRCT2
domain of XRCC1 binds to and stabilizes DNA ligase III
(Lig III) (20,21).
Based on studies with chinese hamster ovary cells lacking
functional XRCC1 expressing different XRCC1 mutants,
Caldecott and co-workers proposed that SSBs repair occurred
via two different XRCC1-dependent pathways [reviewed in
(16) and references therein]. The most rapid pathway, by
which SSBs induced by alkylating agents are rejoined in <3h ,
appears to operate throughout the cell cycle. It requires the
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However, disruption of the BRCT2 does not greatly sensitize
cells to alkylating agents and it has been suggested that
cells possess a second XRCC1-dependent pathway that
operates speciﬁcally in S/G2. The BRCT2 domain and Lig
III are dispensable in this later pathway but the BRCT1
domain is a critical determinant. Therefore, we thought to
identify novel BRCT1 binding proteins that could be involved
in this pathway.
DNA-PK belongs to the phosphatidylinositol 3-kinase-
related kinase (PI3-KK) superfamily, all of them displaying
double-strand breaks (DSBs)-stimulated kinase activity.
DNA-PK is a nuclear serine/threonine kinase composed of a
Ku70/80 heterodimer, which displays high afﬁnity for DNA
termini regardless of sequence context. Subsequently, the
Ku70/80 heterodimer recruits the catalytic subunit (DNA-
PKcs) resulting in kinase activity. Once bound to the DSB,
the DNA-PK holoenzyme facilitates the recruitment of the
heterodimer XRCC4/DNA ligase IV (22,23), which helps to
complete the non-homologous end joining (NHEJ) pathway.
Defect in any of these proteins leads to severe radiosensitivity,
DSBs repair deﬁciency and immunodeﬁciency. Additional
factors are required for NHEJ: PNK that participates in the
phosphorylation of 50 ends (24) and the complex Mre11, Rad
50, Nbs1 (MRN) which plays a key role in aligning DNA ends
in a synaptic complex (25).
In the present work, we report a novel interaction between
XRCC1 and DNA-PK mediated by the BRCT1 domain whose
phosphorylation at serine 371 is stimulated in response to
ionizing radiation (IR) and regulates the dimer/monomer
transition of XRCC1. Reciprocally, XRCC1 stimulates the
kinase activity of DNA-PK on serine 15 of p53 in vitro.
Finally, the non-phosphorylable XRCC1 mutant S371L
expressed in XRCC1-deﬁcient rodent cells (EM9) failed to
fully rescue the DSB repair defect spontaneously present or
induced by a low dose of IR. These results provide insight into
an unexpected interplay between XRCC1 and the hetero-
trimeric complex DNA-PK that contributes to the resolution
of DSB perhaps when a replication fork encounters a SSB.
MATERIALS AND METHODS
Construction of the expression vectors
pCDEX vector encompassing the cDNA encoding human
XRCC1was kindly given by K. Caldecott (Sussex, UK). Trun-
cated forms of XRCC1 were subcloned in-frame with GST in
the eukaryotic pBC vector (26). Construction of the Flag-
tagged XRCC1 encoding plasmid was described elsewhere
(18). The S371L and S371D mutations of XRCC1 were gen-
erated by PCR by changing the AGC codon encoding a serine
by a CTG or a GAT codon encoding a leucine or an aspartic
acid, respectively. The mutated cDNA was cloned in the
pCDEX vector. Wild-type and mutant sequences of human
XRCC1 were cloned into the EcoRI site of pEGFP-C3 vector
(Clontech). P53 oligonucleotides sense: 50-AATTAGA-
ACCTCCACTTTCTCAAGAAGCTTTCGCTGATCTTTG-
GAAGAAAC-30 antisense: 50-TCGAGTTTCTTCCAAAG-
ATCAGCGAAAGCTTCTTGAGAAAGTGGAGGTTCT-30
corresponding to amino acids 11–25were annealed and cloned
in the EcoRI and XhoI sites of the prokaryotic vector pGEX
(Amersham Biosciences). XRCC1 (282–428) including
BRCT1 domain, XRCC1 (282–428) S371L, XRCC1 (282–
428) S371D and XRCC1 (527–633) including BRCT2 domain
cDNAs were ampliﬁed by PCR and cloned in pGEX vector.
GSTfusionproteinswereproducedinEscherichiacoli(BL21)
and soluble proteins were puriﬁed using glutathione–
Sepharose beads as indicated by the manufacturer.
Antibodies, western-blot analysis
Proteins were monitored using the following antibodies: rabbit
polyclonal anti-PARP-1 and anti-XRCC1 (Alexis), goat poly-
clonal anti XRCC1 (D18), rabbit polyclonal anti-DNA-PKcs,
anti-ATM (H248), monoclonal anti-Mycand anti-KU70 (C19)
(Santa-Cruz, Biotechnology), monoclonal anti DNA-PKcs
(Ab4) and anti-KU80 (NeoMarkers), anti-GST (IGBMC,
Illkirch), anti-FLAG M2 (Sigma). Western blotting was car-
ried out by standard procedures and proteins were visualized
by ECL
+ (Amersham).
Mass spectrometry
Gel slices containing protein bands of interest stained with
SYPRO-ruby were excised and processed as described previ-
ously (27). After digestion, the resulting peptide extracts were
directly analyzed by nanoLC-MS/MS. Mass data acquisitions
were piloted by MassLynx software (Micromass) using auto-
matic switching between MS and MS/MS modes.
Immunoprecipitation, pull-down and kinase assays
All steps were performed at 4 C. Cells were washed two times
with ice cold phosphate-buffered saline (PBS). For GST pull-
down assay, cells were lysed in 1 ml LBS buffer (50 mM Tris–
HCl, pH 8, 150 mM NaCl, 0.1% NP-40, 10 mM NaF, 1 mM
Na3VO4, 0.5 mM phenylmethylsulfonyl ﬂuoride (PMSF) with
protease inhibitors (Complete Mini, Roche Molecular Bio-
medicals, Mannheim, Germany). After 20 min, cells were
scraped and centrifuged 20 min at 17 000 g to remove cellular
debris. GST-pull-down assays were performed as described
in (17). For immunoprecipitation assays, nuclear extracts
(100 mg) were precleared with protein-A or -G sepharose
(Amersham Biosciences) for 30 min before addition of anti-
bodies and incubated on a rotating platform for 2 h. Protein A-
or G- sepharose beads were then added for 1 h incubation to
capture immunocomplexes. After washing, bead-containing
pellets were either resuspended in Laemmli buffer or used
in a kinase assay. To this purpose, sepharose beads were
washed twice with 200 ml of kinase buffer (70 mM Tris–
HCl, pH 7.5, 10 mM MgCl2, 5 mM DTT, 10 mM NaF,
1m MN a 3VO4). Beads were incubated with 20 ml of kinase
buffer containing either 0.3 mCi of [
32P]-gATP (Amersham
Biosciences) or 1 mM cold ATP, for 30 min at 30 C. Beads
were washed twice in LBS prior resuspension in Laemmli
buffer. Proteins were separated on SDS–PAGE, transferred
onto nitrocellulose membrane and subjected when necessary
to sequential autoradiography using a phosphoimager
(BioRad) and western blotting analysis.
The speciﬁc DNA-PK inhibitor (NU7441) (28) and ATM
inhibitor KU-55933 (29) were provided by R. Grifﬁn and
KuDOS Pharmaceuticals, Cambridge, UK. Following pull-
down, beads were incubated 1h at 4 C in the presence of
kinase inhibitor (10 mM Wortmanin, 1 mM and 0.1 mM
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kinase buffer. Then beads were incubated with 0.3 mCi of
32P gATP for 30 min at 30 C. Beads were washed 3 times
in LBS in presence of the inhibitors prior resuspension in
Laemmli buffer.
Far western blotting
Puriﬁed proteins: DNA-PKcs (1mg) and the heterodimer
Ku70/Ku80 (2mg) provided by B. Salles, DNA Ligase III
(provided by A. Tomkinson), DNA polymerase b. provided
by Z. Hostomski), GST and BSA (2mg each) were dot-blotted
onto nitrocellulose ﬁlters and subsequently blocked for 30 min
in binding buffer (Tris HCl 50 mM pH 7.5, NaCl 120 mM,
NP40 0.1%, PMSF and 0.5 mM BSA 20 mg/ml). Filters
were then incubated for 1 h at RT in binding buffer containing
5 mg/ml of recombinant XRCC1. Filters were rinsed three
times in binding buffer and bound XRCC1 was revealed by
western-blot with a goat polyclonal anti-XRCC1 antibody
(1/100 in dilution).
Metabolic labeling experiments
HeLa cells (10
6) were plated in 6 cm Petri dishes in normal
medium. After 16 h of serum starvation, cells were washed
with phosphate-free DMEM and then incubated 2 h in the
same medium. Cells were either mock-treated or irradiated
with 10 Gy at a dose-rate of 0.5 Gy/min with an X-ray irra-
diator (Cegelec, France) operating at 100 kV, 9 mA. The cells
were immediately incubated in 1 ml of phosphate-free
DMEM containing 600 mCi of
32P orthophosphate (Amersham
10 mCi/ml) for 3 h. Cells were then washed in phosphate-
free medium and processed as described for XRCC1
immunoprecipitation.
Stimulation of DNA-PK activity
An aliquot of 1 mg of GST-p53 (residues 11–25) substrate was
mixed with different amounts of human XRCC1 (0.25–2 mg),
in kinase buffer containing, 400 ng/ml of DNase I-activated
calf thymus DNA, 1 mM ATP and 20 U of DNA-PK (Pro-
mega) and incubated at 30 C for 10 min. Experiments were
performed using human full-length recombinant XRCC1 or
the XRCC1 BRCT1 (282–428), XRCC1 (282–428) S371L,
XRCC1 (282–428) S371D and XRCC1 BRCT2 (527–633)
in fusion with GST. Kinase reactions were terminated by
addition of Laemmli buffer. Proteins were separated by
SDS–PAGE on 10% acrylamide gels. Phosphorylation of
the p53-Serine15 was monitored using an anti phospho-p53
(ser15) monoclonal antibody (Cell Signaling, Beverly).
Immunofluorescence
Cells (10
4) grown on glass coverslips were treated or not with
1 Gy of X-rays and processed for immunoﬂuorescence after
the indicated time of recovery. Cells were washed twice in
cold PBS, ﬁxed for 10 min at room temperature with PBS, 3%
paraformaldehyde, 2% sucrose followed by washing with PBS
and 0.1% Triton X-100. Cells were then permeabilized for
5 min at 4 C with 0.5% Triton X-100, 20 mM HEPES
pH 7.4, 50 mM NaCl, 3 mM MgCl2, 300 mM sucrose and
washed twice with PBS, 0.1% Triton X-100. Cells were then
incubated 10 min at 37 C with polyclonal anti-gH2AX (Alexis
Biochemicals, Lausen) at 1:1000 in PBS, 2% BSA. After two
washes with PBS, 0.1% Triton X-100, cells were incubated for
10 min at 37 C with an Alexia Fluor 568 goat anti-rabbit IgG
(1:1500, Molecular Probes) in PBS, 2% BSA. Cells were
counterstained with 40,6-diamidino-2-phenylindol (DAPI)
and mounted in MOWIOL. Immunoﬂuorescence was evalu-
ated using a DMRA2 (Leica) microscope, equipped with a
ORCA-ER chilled CCD camera (Hammamatsu) and the cap-
ture software Openlab (Improvision).
RESULTS
Identification by mass spectroscopy of DNA-PKcs
associated with the BRCT1 domain of XRCC1
The evolutionarily conserved BRCT1 domain of XRCC1
derives from an ancestral motif found in rad4/cut5 in
Schizosaccharomyces pombe (30). This domain is essential
for cell survival after MNU treatment (31) and was previously
shown to interact with PARP-1 and PARP-2, two enzymes
involvedingenomemaintenance (17,18).To identify potential
members of the multicomponent DNA repair complex, the
BRCT1 domain (amino acids 282–428) was overproduced
in bacteria in fusion with GST (GST XRCC1 282–428), puri-
ﬁed on glutathione beads and incubated with nuclear extracts
of HeLa cells. Pulled-down interacting proteins were separ-
ated by 10% SDS–PAGE. Multiple bands in the region of 30–
300 kDa were observed, isolated from the gel and analyzed by
proteolytic peptide sequencing. Among these, PARP-1 was
identiﬁed as expected (17). Interestingly, the catalytic subunit
of DNA-PK was identiﬁed by the presence of six different
peptide fragments covering most of this molecule as seen in
Figure 1A.
To conﬁrm whether XRCC1 and DNA-PK coexist in a
common complex, we carried out co-immunoprecipitation
experiments in HeLa nuclear extracts. As shown in
Figure 1B, XRCC1 was co-immunoprecipitated with anti-
DNA-PKcs, anti-Ku80 and anti-Ku70 antibodies but not
with unrelated control anti-Myc or anti-MMP 9 antibodies
(reverse immunoprecipitations are shown in Figure 3E). We
next tested for a direct physical association between XRCC1
and DNA-PKcs and/or the heterodimer Ku70/Ku80 by Far-
western analysis (Figure 1C). Highly puriﬁed DNA-PKcs,
Ku70/Ku80 heterodimer and the two documented XRCC1
binding partners LigIII and DNA polb were dot-blotted
onto nitrocellulose along with the control proteins GST and
BSA. The nitrocellulose ﬁlter was incubated with puriﬁed
XRCC1 and immunostained with an anti-XRCC1 antibody.
As expected, puriﬁed LigIII and DNA polb retained binding to
XRCC1 but not the negative controls GST and BSA. Inter-
estingly, both DNA-PKcs and the heterodimer Ku70/Ku80
were immunostained with the anti-XRCC1 antibody thus
conﬁrming a direct association between XRCC1 and these
proteins.
The BRCT1 domain of XRCC1 interacts with and is
phosphorylated in vitro by DNA-PK
Five overlapping XRCC1 fragments spanning the entire
XRCC1 protein (Figure 2A) fused to the GST protein were
transiently expressed in HeLa cells, puriﬁed on glutathione–
Sepharose beads and analyzed by western blotting with
an anti-GST antibody to assess the expression level of the
34 Nucleic Acids Research, 2006, Vol. 34, No. 1recombinant proteins (Figure 2B). They were subsequently
analyzed by western blotting with anti-DNA-PKcs, anti-
Ku80 and anti-Ku70 antibodies. We found that the three
subunits of DNA-PK co-puriﬁed only with BRCT1 containing
XRCC1-fusion proteins (Figure 2C) conﬁrming that XRCC1
and DNA-PK are present in a complex. XRCC1 (314–428)
encompassing the BRCT1 domain was identiﬁed as the
minimal region interacting with DNA-PK. In contrast, no
co-puriﬁcation of ATM was observed (Figure 2C).
Then, we questioned whether the BRCT1 domain could be
phosphorylated by DNA-PK in vitro. The same truncated frag-
ments of XRCC1 in fusion with GST were used to perform a
kinase assay using [g-
32P]ATP. The proteins were separated
on SDS–PAGE and labeled proteins were autoradiographied.
Interestingly, only the truncated mutants containing the
BRCT1 domain (amino acid 314–428) fused to the GST
were found highly phosphorylated indicating that they are
substrate for the co-purifying DNA-PK (Figure 2D). In this
experiment, the C-terminal peptide of XRCC1 (427–633)
bearing the CK2 phosphorylation sites was not found
phosphorylated.
Human XRCC1 is phosphorylated in vivo
following irradiation
To determine whether XRCC1 is phosphorylated in vivo,
exponentially growing HeLa cells were exposed or
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XRCC1 was monitored, after immunoprecipitation, by
32P
orthophosphate incorporation. In non-irradiated cells,
immunoprecipitated XRCC1 was found phosphorylated
most likely reﬂecting the constitutive phosphorylation by
CK2 (11,12,15). Interestingly, a signiﬁcant stimulation of
32P orthophosphate incorporation into XRCC1 was observed
after IR (Figure 3A). Addition of wortmannin, a PI3 kinase-
like kinase inhibitor (32), decreased the phosphorylation of
XRCC1to the level observed in non irradiated cells,indicating
that as expected, a kinase belonging to the PI3-KK family
phosphorylates XRCC1 in response to IR.
To conﬁrm that XRCC1 BRCT1 domain is phosphorylated
in vivo after DNA damage, HeLa cells expressing GST-
XRCC1(170–428), which contains the NLS and the BRCT1
motif but not the CK2 phosphorylation sites, were either
mock-irradiatedortreated with 10GyIR.Thephosphorylation
of GST-XRCC1(170–428) was monitored by in vivo
32P
orthophosphate incorporation (Figure3B, top). Protein expres-
sions were assessed on the same blot by Western blotting with
an anti-GST antibody (Figure 3B, bottom). A robust stimula-
tion of
32P orthophosphate incorporation was detected after
irradiation, indicating that GST-XRCC1 (170–428) is phos-
phorylated in vivo after IR.
To examine whether an other kinase can be associated with
and phosphorylates the BRCT1 domain, GST-XRCC1(170–
428) was expressed in either DNA-PKcs
+/+ or DNA-PKcs
 / 
mouse embryonic ﬁbroblasts (MEFs) (33), puriﬁed by GST
pull-down and used as substrates for the co-puriﬁed kinase. As
shown in Figure 3C, GST-XRCC1(170–428) was highly phos-
phorylated when expressed in DNA-PKcs
+/+ MEFs but was
phosphorylated to background level when expressed in
DNA-PKcs
 /  MEFs, demonstrating that indeed DNA-
PKcs catalyzes the phosphorylation of XRCC1 BRCT1 and
that no other kinase co-puriﬁed with this BRCT1 containing
truncated protein.
To further identify the kinase responsible for XRCC1 phos-
phorylation, kinase assays were performed in the presence of
speciﬁc PI3-KK inhibitors following pull down of GST-
XRCC1(170–428) in COS-1 cells. As shown in Figure 3D,
the use of 10 mM of the PI3-KK inhibitor wortmannin or 0.1 to
1 mM of the speciﬁc DNA-PK inhibitor NU7741 abolished the
phosphorylation of GST-XRCC1 (170–428). On the opposite,
the use of 10 mM of caffeine or 0.1 mM of the speciﬁc
ATM inhibitor KU-55933 barely affected the reaction, thus
conﬁrming DNA-PK as the major kinase involved in the
phosphorylation of XRCC1 at its BRCT1 domain.
DNA-PK phosphorylates the BRCT1 domain at Ser 371
DNA-PK phosphorylates serines or threonines in a (Ser/Thr)-
Gln motif. Analysis of the human XRCC1 sequence reveals
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Figure 3. XRCC1isphosphorylatedbyDNA-PKinresponsetoIR.(A)Invivo
phosphorylation of XRCC1 induced by irradiation. HeLa cells were left
un-irradiated ( ) or exposed to 10 Gy ionizing radiation (+) and in vivo
metabolically labeled with
32P orthophosphate. When indicated cells were
preincubated with 5 mM wortmannin for 30 min before IR. 3h after IR, cells
were lysed and cell lysates were immunoprecipitated with an anti-XRCC1
antibody. Proteins were analyzed on SDS–PAGE and transferred onto nitro-
cellulose membrane. The membrane was exposed to autoradiography and then
immunoblotted with an anti-XRCC1 antibody. (B) In vivo phosphorylation of
XRCC1 (170–428) induced by irradiation. HeLa cells were transfected with
GST-XRCC1(170–428)-expressing plasmid and treated with 10 Gy IR and
in vivo metabolically labeled with
32P orthophosphate as in (A). Cells were
collected 3 h after and after GST-pull down assays, proteins were separated in
10% SDS–PAGE and autoradiographied. The expression level of GST-
XRCC1(170–428) protein was assessed by anti-GST immunoblotting.
(C) Phosphorylation of XRCC1 in DNA-PKcs
+/+ and DNA-PK cs
 /  MEFs.
MEFs were transfected with GST-XRCC1 (170–428) expressing plasmid.
Kinase assays were performed after GST-pull down experiments. (D) In vitro
phosphorylation of XRCC1 (170–428) in the presence of specific kinase
inhibitors.GSTtaggedXRCC1(170–428)wasexpressedinCOS-1cells.After
GST pull-down, beads were incubated in the presence of 10 mM Wortmannin,
1 mM or 0.1 mM NU7741 (DNA-PK inhibitor), or 10 mM caffeine, 0.1 mMo f
KU-55933 (ATM inhibitors). Following this, kinase assays were performed
with [g-
32P]ATP and proteins were separated in 10% SDS–PAGE, transferred
onto nitrocellulose and phosphorylation of XRCC1was assessed by autoradio-
graphy.(E)PhosphorylationofXRCC1butnotXRCC1S371Linvitro.COS-1
cells were transfected with pCDEX expressing wt full length XRCC1 or with
pCDEXS371L expressingXRCC1S371L.Cellularextracts were immunopre-
cipitated with an anti-XRCC1 antibody and kinase activities were performed
in the absence ( ) or in the presence (+)o f1mM of wortmannin on beads-
associated proteins. Levels of XRCC1, DNA-PKcs, Ku80 and Ku70 were
determined by western blotting.
36 Nucleic Acids Research, 2006, Vol. 34, No. 1the presence of four (Ser/Thr)-Gln motifs, but only one within
theBRCT1domain.Serine371liesintheC-terminalendofthe
XRCC1 BRCT1. To ascertain that the predicted Ser 371 was
the phosphorylation site, we generated the point mutant
XRCC1 S371L and expressed either the wt or the mutant
form of XRCC1 in COS-1 cells. Immunoprecipitated
XRCC1 and XRCC1 S371L were used as substrate in a kinase
assay. Figure 3E reveals that wt XRCC1 is phosphorylated by
the co-immunoprecipitated DNA-PK and the addition of 1 mM
wortmannin in the reaction mixture almost abolished XRCC1
phosphorylation. In clear contrast, XRCC1 S371L was phos-
phorylated to background level as compared with wt XRCC1.
Addition of wortmannin was ineffective on the residual phos-
phorylation of the mutated protein, thus suggesting that the
residual phosphorylation of XRCC1 S371L is most likely
DNA-PK-independent as previously observed in Figure 3C.
To rule out the possibility that XRCC1 S371L was not phos-
phorylated because this mutation affects the interaction of
XRCC1 with DNA-PK, the membrane used for the detection
of XRCC1 was assayed for the presence of DNA-PK hetero-
trimer. As shown in Figure 3E, the same amount of the DNA-
PK heterotrimer co-immunoprecipitated with either wt or
S371L XRCC1, indicating that the phosphorylation status of
Ser371 does not impact on the binding of XRCC1to DNA-PK.
Phosphorylation of serine 371 causes
XRCC1 dimer dissociation
It was recently shown that XRCC1 can form dimers at high
concentration (34,35). As BRCT domains are protein–protein
interaction modules, we reasoned that XRCC1 BRCT1 or
BRCT2 domain might be directly involved in XRCC1 dimer-
ization. To explore this possibility, we examined the ability of
Flag-XRCC1 to interact with GST-XRCC1 truncated proteins
expressed inHeLa cells. Cell extracts expressing Flag-XRCC1
were mixed with cell extracts expressing GST-fused truncated
versions of XRCC1. GST-fused proteins were subsequently
trapped on glutathione–Sepharose beads, and co-purifying
Flag-tagged XRCC1 was assessed by western blot analysis
with an anti-Flag antibody. As shown in Figure 4A,
co-puriﬁcation of Flag-XRCC1 was efﬁcient only with GST-
XRCC1 polypeptides containing the BRCT1 domain, but not
with the GST fusion containing the BRCT2 domain (427–
633). As the former can be phosphorylated by DNA-PK,
we wondered whether the dimerization of XRCC1 depends
on the phosphorylated status of XRCC1 Ser 371. Pulled-down
GST-XRCC1 (170–428) protein was phosphorylated in vitro
by the co-associated DNA-PK in the presence of ATP, or
dephosphorylated with l phosphatase (lPPase). Then, these
bead-associated proteins were mixed to cell extracts contain-
ing Flag-XRCC1 and after centrifugation the co-association
of Flag-XRCC1 was assessed by western blotting. Figure 4B
shows that the phosphorylated form of XRCC1 retains small
amount of Flag-XRCC1. In clear contrast, Flag-XRCC1 lar-
gely co-puriﬁed with dephosphorylated XRCC1. Similar
experiments were conducted with the non-phosphorylable
GST-XRCC1(170–428) S371L mutant and the GST-
XRCC1(170–428) S371D mutant that mimics a
constitutively phosphorylated form of XRCC1. Flag-XRCC1
associated preferentially with the non-phosphorylable
form of XRCC1 (Figure 4C). These results indicate that
hypo-phosphorylation favors XRCC1 dimerization or
higher-order multimerization. Conversely, phosphorylation
at Ser 371 causes XRCC1 dimer dissociation into monomer.
PARP-1 and PARP-2, which are known to form homo and
heterodimers, are partners of XRCC1 BRCT1. Therefore, we
questioned whether XRCC1 dimerization was mediated by
PARP-1 or PARP-2 dimer. To determine this, GST-XRCC1
(282–428) was expressed in E.coli, puriﬁed to homogeneity
and dot-blotted onto nitrocellulose along with the control pro-
teins GST, BSA and Polb. The nitrocellulose ﬁlter was incub-
ated with puriﬁed XRCC1 and immunostained with antibodies
raised against the C-terminal part of XRCC1 which do not
recognize the BRCT1 domain. As shown in Figure 4D, the
BRCT1 domain retained binding to full-length XRCC1 as well
as Polb, indicating a direct association mediated by the
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Figure 4. BRCT1is aninterface fordimerization and Ser 371 phosphorylation
induces dimer dissociation. (A) Mapping of the interface domain for dimer
formation.ExtractsfromHeLa cells expressingFlag-XRCC1weremixed with
extracts from HeLa cells expressing GST or GST-XRCC1-truncated mutants.
Co-purification of Flag-XRCC1 was analyzed after GST-pull-down and
immunoblotting with anti-Flag (top). Blot was subsequently probed with
anti-GST antibody (bottom). (B) Pulled-down GST-XRCC1 (170–428) from
HeLacellswastreatedwithlphosphataseorsupplementedwithATP.Proteins
werethenmixedwithextractsfromHeLacellsexpressingFlag-XRCC1.Inter-
acting proteins were analyzed as in (A). (C) Pulled-down GST-XRCC1 (170–
428) S371L and GST-XRCC1 (170–428) S371D from HeLa cells were mixed
with extracts from HeLa cells expressing Flag-XRCC1. Interacting proteins
were analyzed as in (A). (D) BRCT1 dimerization was confirmed by Far-
western blot. Purified GST-BRCT1 expressed in bacteria was dot-blotted onto
nitrocellulose along with GST, BSA and polb. The filter was incubated with
purified full-length XRCC1 and bound XRCC1 was revealed with an anti-
XRCC1 antibody raised against a C-terminal peptide.
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was observed with the negative controls GST and BSA.
XRCC1 stimulates DNA-PK catalytic activity in vitro
It has been shown that XRCC1 interacts with and stimulates
PNK, DNA Ligase III and APE1 activities (6,8,20). In con-
trast, XRCC1 negatively regulates PARP-1 and PARP-2
enzymatic activities (17,18). We therefore examined whether
XRCC1 might affect the enzymatic activity of DNA-PK. An
in vitro DNA-PK assay was set up with puriﬁed DNA-PK,
a recombinant peptide encompassing the serine 15 of p53
fused to GST as substrate and increasing amounts of recom-
binant XRCC1. We examined the Ser-15 phosphorylation
status of p53 by immunoblotting using an anti-p53 phospho-
Ser-15 speciﬁc antibody. In the absence of DNA-PK no
phosphorylation of p53 peptide on Ser15 was observed
(Figure 5A). Addition of increasing amounts of recombinant
human XRCC1 to the reaction strongly stimulated DNA-PK-
dependent p53-Ser 15 phosphorylation. Heat-inactivated
XRCC1 was not able to stimulate DNA-PK activity (data
not shown). Since XRCC1 BRCT1 was found as the interact-
ing domain with DNA-PK, the possibility that this domain
alone stimulates DNA-PK activity was investigated. Bacteri-
ally puriﬁed GST-XRCC1 BRCT1 (282–428), the mutated
versions S371L and S371D as well as the GST-XRCC1
BRCT2 (527–633) were used in the in vitro kinase assay.
The addition to the reaction mixture of GST-XRCC1
BRCT1 and the mutant S371L strongly stimulated DNA-
PK activity in vitro (Figure 5B), whereas the addition of
GST-XRCC1 (282–428) S371D only slightly stimulated the
reaction. The addition of GST-XRCC1 (427–633) comprising
the BRCT2 domain had no stimulatory effect at all. These
results indicate that the BRCT1 domain is endowed with
the capacity to stimulate DNA-PK activity, depending on
the Ser 371 status (Figure 5B). Taken together, these data
indicate that XRCC1 strongly stimulates DNA-PK activity
and that this stimulatory effect is weakened in the mutant
S371D that mimics a phosphorylated status of the BRCT1
domain.
XRCC1 phosphorylation at Serine 371
is important for DSB rejoining
To directly investigate the biological signiﬁcance of XRCC1
phosphorylation at Serine 371 in relation of rejoining DSBs,
we took advantage of g-H2AX foci analysis as a sensitive
monitor of DSBs formation and repair (36,37). In the absence
of DNA damage, we found that the ‘spontaneous’ level of g-
H2AX foci was higher in XRCC1-deﬁcient EM9 cells than in
wt AA8(Figure 6A)(t-test,P < 0.001)inagreementwith (38).
We further investigated the biological signiﬁcance of
XRCC1 phosphorylation at S371 in relation to DSBs occur-
rence and repair in vivo in EM9 cells corrected for either wt or
S371L-mutant XRCC1 (Figure 6B and C). Interestingly, in the
absence of DNA damage, the expression of either XRCC1 or
XRCC1 S371L in EM9 cells decreased substantially the aver-
agenumberofg-H2AXfocipernucleus. However,thenumber
of foci in cells restored with the non-phosphorylable XRCC1
was signiﬁcantly higher compared with that restored with wt
XRCC1 (t-test P < 0.001). Following 1 Gy IR, g-H2AX foci
increased substantially inall cell lines. Interestingly, the defect
was substantially corrected in EM9 cells expressing wt
XRCC1. In contrast, the S371L XRCC1 mutant that disrupts
the DNA-PK phosphorylation site failed to rescue completely
the DSB repair defect of EM9 cells (Figure 6B and C).
Together, these results provide compelling evidence that phos-
phorylation of XRCC1 at Serine 371 is important for rejoining
of DSBs in response to DNA damage caused by IR.
DISCUSSION
Using a combination of IP, reverse IP and GST pull-down
analysis, in this work we provide evidence of a physical
and functional association of XRCC1 with the heterotrimeric
complex DNA-PK. In vivo metabolic labeling showed that
XRCC1 is constitutively phosphorylated and that it is further
hyper-phosphorylated following IR. Both the use of speciﬁc
PI3-KK inhibitors and DNA-PKcs
 /  MEFs conﬁrmed that
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Figure 5. XRCC1 stimulates DNA-PK enzymatic activity. (A) Stimulation of
DNA-PK activity by XRCC1. DNA-PK was incubated with GST-p53 (amino
acids 11–25) in presence of ATP and DNAse I-activated DNA. Increased
amounts of XRCC1 were added to the reaction (0.5, 1 and 2 mg). Proteins were
separated by gel electrophoresis and phosphorylation of GST-p53 (11–25) was
probed with anti-p53 P-Ser15 monoclonal antibody. (B) Stimulation of DNA-
PK activity by GST-XRCC1 (282–428) comprising the BRCT1 domain, GST-
XRCC1 (282–428) S371L, GST-XRCC1 (282–428) S371D and GST-XRCC1
(537–633) comprising the BRCT2 domain. Same reactions as in A, excepted
thatincreasedamounts(1and2mg)ofthedifferenttruncatedmutantsareadded
instead of full length. Phosphorylation of GST-p53 (11–25) on Ser 15 was
probed as in (A). The same amount of GST-p53 was added in each reaction
as confirmed by an anti-GST antibody.
38 Nucleic Acids Research, 2006, Vol. 34, No. 1DNA-PK is the major kinase involved in the phosphorylation
of the BRCT1 domain at Ser 371. It has been suggested that an
altered DNA repair activity of XRCC1 R399Q polymorphism
may contribute to susceptibility to carcinogenesis. However,
EM9 cells expressing wt or XRCC1 R399Q failed to reveal
any difference in the sensitivity to MMS and in SSB repair
(31). Therefore, because the mutation of R399 could have an
impact on the structure around S371 and consequently on the
BRCT1 phosphorylation, the R399Q mutant was tested for its
ability to be phosphorylated by DNA-PK in vitro. We found
that XRCC1 R399Q is associated with and can be phos-
phorylated on S371 by DNA-PK similarly to wt XRCC1
(data not shown), thus ruling out a disturbing effect of this
polymorphism on BRCT1 phosphorylation.
It has been previously reported that XRCC1 is multiply
phosphorylated by CK2 (11,12,15). The CK2 phosphorylation
sites were mapped on a cluster of serine/threonine located in
the linker between the two BRCT domains (11,12). XRCC1
phosphorylation by CK2 promotes interaction with PNK (11).
PNK was previously shown to stimulate both DNA kinase and
DNA phosphatase activities at DNA breaks (8), therefore
stimulating DNA repair. CK2 phosphorylation of XRCC1
also regulates binding of Aprataxin, the protein mutated in
ataxia-oculomotor apraxia 1 (AOA1) (39,40), to the same
region of XRCC1 competitively (12). Thus, XRCC1 binds
to PNK or Aprataxin in a mutually exclusive manner. In
this work, no protein kinase activity was found associated
with the C-terminus of XRCC1 (XRCC1 428–633) encom-
passing the CK2 phosphorylation sites suggesting that CK2
does not co-purify with this domain under the conditions we
have used.
Independent and important roles have been ascribed to each
XRCC1 BRCT domain (15,16). The BRCT1 domain is the
most evolutionarily conserved and is required for survival
after methylation damage but its precise function is not
fully understood at present. It mediates the interaction with
PARP-1 (17) and PARP-2 (18) and contains a binding site for
poly(ADP–ribose) (19). In response to DNA damage-induced
SSBs, XRCC1 is recruited within seconds to the sites of chro-
mosomal DNA strand breakage by its BRCT1 domain (3–5).
We found that Ser 371 phosphorylation is not involved in this
process since XRCC1 S371L can still be recruited to DNA
damagesites (datanotshown).Incontrasttotworecent reports
showing that XRCC1 dimerizes via its BRCT2 domain
(34,35), we showed here by GST-pull down assay and Far-
western blotting that the BRCT1 (but not the BRCT2) domain
is the interface for homodimerization or formation of higher
order multimer complex. We also show that BRCT1 phos-
phorylation on Ser 371 controls XRCC1 dimer-monomer
transition that reﬂects a major structural change of XRCC1
after BRCT1 phosphorylation. The DSBs repair delay
observed with the ectopic expression of the non-
phosphorylable mutant S371L emphasizes the importance
of the phosphorylation of XRCC1 and hence its conversion
to a monomeric form, in the resolution of IR-induced DSBs.
Interestingly, in the crystal structure of tandem BRCT repeats
like 53BP1 or BRCA1 (41,42), the position equivalent to Ser
371 in XRCC1 corresponds to a residue localized in helix 2
that contributes to the inter-BRCT repeat interface, thus
inviting to the speculation that phosphorylation of this pos-
ition might strongly perturb BRCT-BRCT interaction thus
preventing dimerization.
The interaction between DNA-PK and XRCC1 not only
triggers the phosphorylation of the BRCT1 domain but also
enhances the phosphorylation of p53-Ser 15. Interestingly, the
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spontaneously or following X-ray irradiation. (A) Spontaneous g-H2AX foci
analysisinwild-typeAA8cellsorinEM9cells(BandC)g-H2AXfocianalysis
in EM9 cells expressing XRCC1 or XRCC1 S371L, after exposure to 1Gy
X-ray. Error bars represent the SEM from three experiments. (* P < 0.05,
*** P < 0.001).
Nucleic Acids Research, 2006, Vol. 34, No. 1 39pseudo phosphorylated mutant S371D did not form dimers of
XRCC1 and was impaired in this stimulatory function. Phos-
phorylation of p53-Ser15 is known to play a role in the func-
tional interactions with early complexes of Rad51-dependent
recombinationandinDNA damage signaling(43,44).Itisthus
tempting to speculate that after a SSB-induced replication fork
stalling XRCC1 as an early responder may channel repair into
the NHEJ. Recent reports suggest a contribution of PARP-1,
XRCC1 (45) and DNA ligase III (46) in backup pathways of
double-strand end-joining. Whether speciﬁc factors involved
in DSBs repair interact with phosphorylated XRCC1 awaits
further investigation.
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